Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous group of liver diseases
characterized by the accumulation of fat in the liver. The heterogeneity of NAFLD is reflected …

The number of patients with nonalcoholic fatty liver diseases (NAFLD) including
nonalcoholic steatohepatitis (NASH), has been increasing. NASH causes cirrhosis and …

Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease worldwide. In subset
of patients, NAFLD progresses to its advanced form, nonalcoholic steatohepatitis (NASH) …

Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F
(UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part …

Purpose To assess safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and
antitumor activity of DEBIO1143, an antagonist of inhibitor apoptosis proteins. Methods This …

Recent studies have identified a cholestatic variant of nonalcoholic fatty liver disease
(NAFLD) with portal inflammation and ductular reaction. Based on reports of biliary damage …

Apoptosis is an early event of steatohepatitis in non-alcoholic fatty liver disease (NAFLD),
and an increase in oxidative stress induced by hyperglycemia has been linked to an …

Nonalcoholic steatohepatitis (NASH) patients have elevated plasma saturated free fatty acid
levels. These toxic fatty acids can induce liver cell death and our recent results …

Background Treatment of acute myeloid leukemia (AML) remains difficult owing to the
development of treatment resistance, which might be overcome through antagonists of …

Nonalcoholic fatty liver disease is a major liver disease that leads to cirrhosis and/or
hepatocellular carcinoma in a subset of patients. The mechanism underlying disease …